SuperworthPuma Biotechnology profit margin PBYI
Gross, operating and net profit as a share of revenue over the last twelve months, from 2018.
- Net margin, 12 months
- 11.6%
- Operating margin, 12 months
- 13.2%
- Net margin on a year earlier
- −8.8 pts
- Peer median
- 22.1%
Over the twelve months to Jun 30, 2026, Puma Biotechnology kept 11.6% of its revenue as net profit, with an operating margin of 13.2% and a gross margin of 74.8%.
Five years earlier its net margin was −13.7%.
The median for 10 large drugmakers of a similar size is 22.1%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 13.6% | 16.3% | 74.5% |
| FY2024 | 13.1% | 13.4% | 72.1% |
| FY2023 | 9.2% | 13.9% | 73.4% |
| FY2022 | 0.0% | 10.4% | 75.8% |
| FY2021 | −11.5% | 0.5% | 74.8% |
| FY2020 | −26.7% | −13.5% | n/a |
| FY2019 | −27.8% | −14.3% | n/a |
| FY2018 | −45.3% | −37.7% | 86.2% |
| FY2017 | n/a | n/a | n/a |
| FY2016 | n/a | n/a | n/a |
| FY2015 | n/a | n/a | n/a |
| FY2014 | n/a | n/a | n/a |
| FY2013 | n/a | n/a | n/a |
| FY2012 | n/a | n/a | n/a |
| FY2011 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 11.6% | −8.8 pts | 13.2% | |
| Q1 FY26 | 10.7% | −5.6 pts | 13.0% | |
| Q4 FY25 | 13.6% | +0.5 pts | 16.3% | |
| Q3 FY25 | 17.4% | +7.9 pts | 15.8% | |
| Q2 FY25 | 20.4% | +16.4 pts | 19.3% | |
| Q1 FY25 | 16.4% | +9.6 pts | 16.0% | |
| Q4 FY24 | 13.1% | +4.0 pts | 13.4% | |
| Q3 FY24 | 9.5% | +7.9 pts | 13.3% | |
| Q2 FY24 | 4.0% | +5.0 pts | 8.6% | |
| Q1 FY24 | 6.8% | +4.7 pts | 11.5% | |
| Q4 FY23 | 9.2% | +9.2 pts | 13.9% | |
| Q3 FY23 | 1.6% | −2.9 pts | 12.2% |
Against its peers
Companies in Drug Manufacturers - General nearest Puma Biotechnology's size, closest first, today.
| Company | Profit margin |
|---|---|
| PBYIPuma Biotechnology | 11.6% |
| IRWDIronwood Pharmaceuticals | 33.4% |
| ZVRAZevra Therapeutics | 42.8% |
| CRMDCorMedix | 40.5% |
| ARVNArvinas | 2.9% |
| COLLCollegium Pharmaceutical | 5.9% |
| ABUSArbutus Biopharma | 84.2% |
| AMPHAmphastar Pharmaceuticals | 10.8% |
| OMEROmeros | n/m |
| PCRXPacira BioSciences | 2.0% |
| ANABAnaptysbio | n/m |
| Peer median | 22.1% |
Where Puma Biotechnology ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Puma Biotechnology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.